Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria

Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria

Cerebral malaria (CM) is a life-threatening neurological complication caused by Plasmodium falciparum. About 627,000 patients died of malaria in 2020. Currently, artemisinin and its derivatives are the front-line drugs used for the treatment of cerebral malaria. However, they cannot target the brain...

Full description

Bibliographic Details
Main Authors: Gu, L. (Author), Li, Y. (Author), Liu, S. (Author), Mu, J. (Author), Shen, S. (Author), Tian, Y. (Author), Wang, X. (Author), Zheng, X. (Author), Zheng, Z. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Artemisinin
Blood
Blood Brain Barrier
Blood-brain barrier
Brain
Brain-targeted liposome
Brain-targeted liposomes
Cerebral malaria
Diseases
Dynamics simulation
Glucose
Glucose transporter-1
GLUT1
Liposomes
Mammals
Molecular dynamics
Nano-delivery systems
Phospholipids
Plasmodium falciparum
Synthesised
Targeted drug delivery
Undecanoic acid
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items